Kevin C. Gorman Ph.D.
Net Worth

Last updated:

What is Kevin C. Gorman Ph.D. net worth?

The estimated net worth of Dr. Kevin C. Gorman Ph.D. is at least $129,917,629 as of 13 Feb 2024. He owns shares worth $68,343,495 as insider, has earned $32,594,134 from insider trading and has received compensation worth at least $28,980,000 in Neurocrine Biosciences, Inc..

What is the salary of Kevin C. Gorman Ph.D.?

Dr. Kevin C. Gorman Ph.D. salary is $1,380,000 per year as Chief Executive Officer & Director in Neurocrine Biosciences, Inc..

How old is Kevin C. Gorman Ph.D.?

Dr. Kevin C. Gorman Ph.D. is 67 years old, born in 1958.

What stocks does Kevin C. Gorman Ph.D. currently own?

As insider, Dr. Kevin C. Gorman Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Neurocrine Biosciences, Inc. (NBIX) Chief Executive Officer & Director 514,596 $132.81 $68,343,495

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

NBIX logo
NBIX
Neurocrine Biosciences, Inc.
$132.81

Kevin C. Gorman Ph.D. insider trading

Neurocrine Biosciences, Inc.

Dr. Kevin C. Gorman Ph.D. has made 60 insider trades between 2004-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 308,250 units of NBIX stock on 8 Jan 2021. As of 13 Feb 2024 he still owns at least 514,596 units of NBIX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 2,778 $35.99 $99,980
Sale
Common Stock 2,832 $133.02 $376,701
Option
Common Stock 2,312 $43.24 $99,971
Option
Incentive Stock Option 5,090 $39.62 $201,640
Sale
Common Stock 2,707 $140.69 $380,845
Option
Non-Qualified Stock Option 62,023 $19.59 $1,215,031
Option
Common Stock 62,023 $19.59 $1,215,031
Sale
Common Stock 62,023 $134.01 $8,311,888
Option
Non-Qualified Stock Option 105,835 $19.59 $2,073,308
Option
Common Stock 105,835 $19.59 $2,073,308
Sale
Common Stock 105,835 $132.44 $14,016,576
Sale
Common Stock 9,328 $107.4 $1,001,818
Sale
Common Stock 2,274 $104.3 $237,185
Sale
Common Stock 20,482 $102.43 $2,098,053
Sale
Common Stock 3,248 $102.3 $332,267
Sale
Common Stock 3,040 $105.68 $321,258
Sale
Common Stock 2,707 $110.08 $297,997
Sale
Common Stock 2,274 $79.49 $180,767
Sale
Common Stock 2,422 $80.83 $195,758
Sale
Common Stock 3,248 $80.83 $262,520
Sale
Common Stock 3,040 $80.8 $245,629
Sale
Common Stock 10,466 $116.75 $1,221,885
Sale
Common Stock 10,466 $38.93 $407,441
Sale
Common Stock 2,422 N/A N/A
Option
Common Stock 308,250 $59.44 $18,322,688
Option
Common Stock 308,250 N/A N/A
Option
Non-Qualified Stock Option 143,449 N/A N/A
Sale
Common Stock 143,449 N/A N/A
Sale
Common Stock 3,390 N/A N/A
Sale
Common Stock 3,390 N/A N/A
Sale
Common Stock 2,906 N/A N/A
Sale
Common Stock 3,248 N/A N/A
Sale
Common Stock 4,343 N/A N/A
Sale
Common Stock 5,449 N/A N/A
Option
Common Stock 3,031 N/A N/A
Option
Incentive Stock Option 3,031 N/A N/A
Option
Non-Qualified Stock Option 26,330 N/A N/A
Option
Common Stock 26,330 N/A N/A
Sale
Common Stock 26,330 N/A N/A
Option
Non-Qualified Stock Option 2,759 N/A N/A
Sale
Common Stock 2,759 N/A N/A
Option
Common Stock 2,759 N/A N/A
Sale
Common Stock 50,911 N/A N/A
Option
Common Stock 50,911 N/A N/A
Option
Non-Qualified Stock Option 50,911 N/A N/A
Sale
Common Stock 4,096 N/A N/A
Sale
Common Stock 4,489 N/A N/A
Sale
Common Stock 3,125 N/A N/A
Option
Incentive Stock Option 24,032 N/A N/A
Option
Common Stock 57,924 N/A N/A
Option
Incentive Stock Option 24,032 $19.38 $465,620
Sale
Common Stock 126,832 N/A N/A
Option
Common Stock 126,832 N/A N/A
Option
Non-Qualified Stock Option 126,832 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Option
Non-Qualified Stock Option 100,000 N/A N/A
Option
Common Stock 100,000 N/A N/A
Sale
Common Stock 5,983 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Option
Employee Stock Option (right to buy) 21,739 N/A N/A
Option
Common Stock 21,739 N/A N/A
Sale
Common Stock 21,739 N/A N/A
Sale
Common Stock 19,596 N/A N/A
Option
Common Stock 64,161 N/A N/A
Option
Employee Stock Option (Right to Buy) 64,161 N/A N/A
Sale
Common Stock 3,010 N/A N/A
Sale
Common Stock 3,125 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Option
Common Stock 9,100 N/A N/A
Option
Employee Stock Option (right to buy) 9,100 N/A N/A
Sale
Common Stock 3,125 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Sale
Common Stock 33,500 N/A N/A
Option
Common Stock 40,000 N/A N/A
Sale
Common Stock 40,000 N/A N/A
Option
Nonqualified Stock Option 40,000 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Sale
Common Stock 3,750 N/A N/A
Option
Common Stock 25,000 N/A N/A
Sale
Common Stock 25,000 N/A N/A
Option
Nonqualified Stock Option 25,000 N/A N/A
Option
Incentive Stock Option 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Sale
Common Stock 25,000 N/A N/A
Option
Common Stock 70,000 $16.61 $1,162,910
Option
Common Stock 70,000 N/A N/A
Option
Nonqualified Stock Option 39,474 N/A N/A
Option
Incentive Stock Option 15,526 N/A N/A
Option
Nonqualified Stock Option 39,474 $1.3 $51,119
Sale
Common Stock 3,750 $18.57 $69,638
Sale
Common Stock 108,000 $16.76 $1,810,080
Sale
Common Stock 15,400 $6.83 $105,136
Sale
Common Stock 15,609 $2.53 $39,491
Sale
Common Stock 9,445 $2.52 $23,830
Sale
Common Stock 15,146 $3.43 $51,920
Sale
Common Stock 9,195 $3.37 $31,015
Sale
Common Stock 8,230 $5.05 $41,537
Sale
Common Stock 3,000 $62.89 $188,679
Sale
Common Stock 6,000 $57.37 $344,220

Neurocrine Biosciences key executives

Neurocrine Biosciences, Inc. executives and other stock owners filed with the SEC: